D‐Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study

Abstract

Patients with chronic coronary heart disease often suffer from congestive heart failure (CHF) despite multiple drug therapies. D-Ribose has been shown in animal models to improve cardiac energy metabolism and function following ischaemia. This was a prospective, double blind, randomized, crossover design study, to assess the effect of oral D-ribose supplementation on cardiac hemodynamics and quality of life in 15 patients with chronic coronary artery disease and CHF. The study consisted of two treatment periods of 3 weeks, during which either oral D-ribose or placebo was administered followed by a 1-week wash out period, and then administration of the other supplement. Assessment of myocardial functional parameters by echocardiography, quality of life using the SF-36 questionnaire and functional capacity using cycle ergometer testing was performed. The administration of D-ribose resulted in an enhancement of atrial contribution to left ventricular filling (40"11 vs. 45"9%, Ps 0.02), a smaller left atrial dimension (54"20 vs. 47"18 ml, Ps0.02) and a shortened E wave deceleration (235"64 vs. 196"42, Ps0.002) by echocardiography. Further, D-ribose also demonstrated a significant improvement of the patient's quality of life (417"118 vs. 467"128, P(0.01). In comparison, placebo did not result in any significant echocardiographic changes or in quality of life. This feasibility study in patients with coronary artery disease in CHF revealed the beneficial effects of D-ribose by improving diastolic functional parameters and enhancing quality of life.

Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review

“…Health-related measures were used in 46 studies. In the majority (52%), the measure of choice was the 36-item Short-form Health Survey (SF-36) or some subscale(s) of the SF-36 (24 studies) [61][62][63][64][65]10,[66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82]. In six studies, this was the only QoL measure used.…”

Intracellular ATP Influences Synaptic Plasticity in Area CA1 of Rat Hippocampus via Metabolism to Adenosine and Activity-Dependent Activation of Adenosine A1Receptors

“…Accordingly, elevation of tissue ATP levels with Rib/Ade may be of value in the postischemic brain. In fact, Rib has been used to improve postischemic cardiac function in vitro, in vivo, and in humans (Zimmer, 1998;Omran et al, 2003;Shecterle et al, 2010). Although Ade has to be administered with a xanthine oxidase inhibitor (Watts et al, 1974;Simmonds, 1986) to prevent its conversion to an insoluble metabolite, this may be beneficial (Phillis et al, 1995) because it would prevent the formation of nonsalvageable xanthine, thereby providing greater substrates for the purine salvage pathway in the post-ischemic brain.…”

Assessment of Hematological and Biochemical parameters with extended D-Ribose ingestion

“…Pre-clinical studies have demonstrated the recovery benefits in depressed high-energy phosphates with D-ribose as well as functional improvements in the myocardium following ischemia and in isolated skeletal muscle [1][2][3][4]. Clinically, congestive heart failure patients have experienced improvements in their diastolic dysfunction, ventilatory efficiency, a better quality of life, and improved physical function activities when taking oral D-ribose [5][6][7]. The benefits in sports medicine have not been as obvious.…”